Cerevance today announced plans to present at the Alzheimer’s Research UK Conference 2023, held in Aberdeen, Scotland and virtually from March 14-15, 2023.
Cerevance today announced plans to present at the Alzheimer’s Research UK Conference 2023, held in Aberdeen, Scotland and virtually from March 14-15, 2023.
Cerevance today announced the publication in Organic Process Research and Development entitled, “Scalable Synthesis of CVN424, an Inverse Agonist of the GPR6 Receptor”.
Cerevance, today announced that Craig Thompson, chief executive officer of Cerevance, will participate in the upcoming SVB Global Biopharma Conference.
Craig Thompson, chief executive officer of Cerevance, will present at the upcoming RBC Capital Markets Virtual Healthcare Private Company Conference being held virtually December 14-15, 2022.
Cerevance today announced a multi-year strategic research collaboration with Merck, known as MSD outside the United States and Canada, to identify novel targets for Alzheimer’s disease utilizing Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform.
Carrie Cook, chief business officer (CBO) of Cerevance, will participate in a fireside chat during the 5th Annual LSX World Congress USA being held in Boston, MA, June 21-22.
Craig Thompson, chief executive officer of Cerevance, will participate in a panel discussion during the 2022 BIO International Convention being held in San Diego, CA, June 13-16.